Getting competition down to a science: The effects of technological competition on firms' scientific publications

Organization Science

Volumn 23, Issue 4, 2012, Pages 1135-1153

  Polidoro, Francisco ^a   Theeke, Matt ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Imitation; Innovations; Knowledge based competitive advantage; Pharmaceutical drugs; Scientific community; Scientific publications; Substitution; Technological competition; Top medical journals

Indexed keywords

EID: 84867074535     PISSN: 10477039     EISSN: 15265455     Source Type: Journal    
DOI: 10.1287/orsc.1110.0684     Document Type: Article

References (90)

1. Afuah, A. 2002. Mapping technological capabilities into product markets and competitive advantage: The case of cholesterol drugs. Strategic Management J. 23(2) 171-179.
2. Akerlof, G. A. 1970. The market for " lemons" : Quality uncertainty and the market mechanism. Quart. J. Econom. 84(3) 488-500.
3. Anderson, P., M. L. Tushman. 1990. Technological discontinuities and dominant designs: A cyclical model of technological change. Admin. Sci. Quart. 35(4) 604-633.
4. Angell, M. 2008. Industry-sponsored clinical research. J. Amer. Medical Assoc. 300(9) 1069-1071.
5. Appel, L. J. 2002. The verdict from ALLHAT-Thiazide diuretics are the preferred initial therapy for hypertension. J. Amer. Medical Assoc. 288(23) 3039-3042.
6. Arrow, K. J. 1962. Economic welfare and the allocation of resources for invention. The Rate and Direction of Inventive Activity: Economic and Social Factors-National Bureau of Economic Research. Princeton University Press, Princeton, NJ, 602-626.
7. Avorn, J., M. Chen, R. Hartley. 1982. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Amer. J. Medicine 73(1) 4-8.
8. Azoulay, P. 2002. Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4) 551-594.
9. Balter, W., M. Skelton, P. O. Safir. 2003. The p's and q's of publication planning. Pharmaceutical Executive 23(5) 130-136.
10. Barney, J. 1991. Firm resources and sustained competitive advantage. J. Management 17(1) 99-120.
11. Bijker, W. E. 1987. The social construction of Bakelite: Toward a theory of invention. W. E. Bijker, T. P. Hughes, T. J. Pinch, eds. The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. MIT Press, Cambridge, MA, 159-190.
12. Blumenthal, D., N. Causino, E. Campbell, K. S. Louis. 1996. Relationships between academic institutions and industry in the life sciences-An industry survey. New Engl. J. Medicine 334(6) 368-373.
13. Bodewitz, H. J. H. W., H. Buurma, G. H. de Vries. 1987. Regulatory science and the social management of trust in medicine. W. E. Bijker, T. P. Hughes, T. J. Pinch, eds. The Social Construction of Technological Systems: New Directions in the Sociology and History of Technology. MIT Press, Cambridge, MA, 243-260.
14. Bosch, J.-C., I. Lee. 1994. Wealth effects of Food and Drug Administration (FDA) decisions. Managerial Decision Econom. 15(6) 589-599.
15. Carpenter, D. P. 2004. The political economy of FDA drug review: Processing, politics, and lessons for policy. Health Affairs 23(1) 52-63.
16. Center for Drug Evaluation and Research. 2005. Report to the nation: Improving public health through human drugs. Report, U.S. Department of Health and Human Services, Washington, DC. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078935.pdf.
17. Christensen, C. M. 1997. The Innovator's Dilemma: The Revolutionary Book that Will Change the Way You Do Business. Harvard Business School Press, Boston.
18. Cockburn, I. M., R. M. Henderson. 1998. Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. J. Indust. Econom. 46(2) 157-182.
19. Cohen, M. D., P. Bacdayan. 1994. Organizational routines are stored as procedural memory: Evidence from a laboratory study. Organ. Sci. 5(4) 554-568.
20. Danzon, P. M. 2000. The pharmaceutical industry. B. Bouckaert, G. De Geest, eds. The Encyclopedia of Law and Economics. Edward Elgar, Cheltenham, UK, 1055-1091.
21. Dasgupta, P. 1988. Patents, priority and imitation, or the economics of races and waiting games. Econom. J. 98(389) 66-80.
22. DiMaggio, P. J., W. W. Powell. 1983. The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. Amer. Sociol. Rev. 48(2) 147-60.
23. DiMasi, J. A. 2001. Risks in new drug development: Approval success rates for investigational drugs. Clinical Pharmacol. Ther. 69(5) 297-307
24. DiMasi, J. A., C. Paquette. 2004. The economics of follow-on drug research and development: Trends in entry rates and the timing of development. Pharmacoeconomics 22(2 Supplement 2) 1-14.
25. Dosi, G. 1982. Technological paradigms and technological trajectories. Res. Policy 11(3) 147-162.
26. Furberg, C. D., D. M. Herrington, B. M. Psaty. 1999. Are drugs within a class interchangeable? Lancet 354(9185) 1202-1204.
27. Gambardella, A. 1992. Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s. Res. Policy 21(5) 391-407.
28. Garud, R., M. A. Rappa. 1994. A socio-cognitive model of technology evolution: The case of cochlear implants. Organ. Sci. 5(3) 344-362.
29. Garud, R., S. Jain, A. Kumaraswamy. 2002. Institutional entrepreneurship in the sponsorship of common technological standards: The case of Sun Microsystems and Java. Acad. Management J. 45(1) 196-214.
30. Gittelman, M., B. Kogut. 2003. Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns. Management Sci. 49(4) 366-382.
31. Godin, B. 1996. Research and the practice of publication in industries. Res. Policy 25(4) 587-606.
32. Greene, W. H. 2003. Econometric Analysis, 5th ed. Prentice Hall, Upper Saddle River, NJ.
33. Griliches, Z. 1990. Patent statistics as economic indicators: A survey. J. Econom. Literature 28(4) 1661-1707.
34. GSAS Harvard Biotechnology Club. 2000. Retrieved September 24, 2009, http://www.thebiotechclub.org.
35. Hansen, M. T., M. R. Haas. 2001. Competing for attention in knowledge markets: Electronic document dissemination in a management consulting company. Admin. Sci. Quart. 46(1) 1-28.
36. Hannan, M., J. Freeman. 1977. The population ecology of organizations. Amer. J. Sociol. 88 1116-1145.
37. Hargadon, A. B., Y. Douglas. 2001. When innovations meet institutions: Edison and the design of the electric light. Admin. Sci. Quart. 46(3) 476-501.
38. Hausman, J. A., B. H. Hall, Z. Griliches. 1984. Econometric models for count data with an application to the patents-R&D relationship. Econometrica 52(4) 909-938.
39. Henderson, R., I. Cockburn. 1994. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management J. 15(S1) 63-84.
40. Hicks, D. 1995. Published papers, tacit competencies and corporate management of the public/private character of knowledge. Indust. Corporate Change 4(2) 401-424.
41. Hosaka, T. 1998. Use beta blockers more, studies suggest: Two new reports on heart attack patients emphasize the benefits of these drugs. Washington Post (August 25) Z07.
42. Jones, M. I., S. M. Greenfield, C. P. Bradley. 2001. Prescribing new drugs: Qualitative study of influences on consultants and general practitioners. British Medical J. 323(7309) 378-381.
43. Jones, N. 2009. Ghosts still present in the medical machine. Nature 461(7262) 325.
44. Kalra, P. A., H. Mamtora, A. M. Holmes, S. Waldek. 1990. Renovascular disease and renal complications of angiotensinconverting enzyme inhibitor therapy. Quart. J. Medicine 77(282) 1013-1018.
45. Kaplan, S., M. Tripsas. 2008. Thinking about technology: Applying a cognitive lens to technical change. Res. Policy 37(5) 790-805.
46. Kennedy, H. L., R. Rosenson. 2002. Physicians' interpretation of " class effects" : A need for thoughtful re-evaluation. J. Amer. College Cardiol. 40(1) 19-26.
47. Kleschick, W. A., S. Lubetkin, G. R. Oliver, S. H. Hutchins, R. K. D. Peterson. 2001. Publish or perish: A business and professional argument for private-sector scientists to publish in refereed journals. Amer. Entomologist 47(2) 69-73.
48. Kogut, B., U. Zander. 1992. Knowledge of the firm, combinative capabilities, and the replication of technology. Organ. Sci. 3(3) 383-397.
49. Landefeld, C. S., M. A. Steinman. 2009. The Neurontin legacy- Marketing through misinformation and manipulation. New Engl. J. Medicine 360(2) 103-106.
50. Lauritsen, K., T. Havelund, L. S. Laursen, J. Rask-Madsen. 1987. Withholding unfavourable results in drug company sponsored clinical trials. Lancet 1(8541) 1091.
51. Law, M., N. Wald, J. Morris. 2003. Lowering blood pressure to prevent myocardial infarction and stroke: A new preventative strategy. Health Tech. Assessment 7(31) 1-94.
52. Lexchin, J., L. A. Bero, B. Djulbegovic, O. Clark. 2003. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical J. 326(7400) 1167-1170.
53. Liebeskind, J. 1996. Knowledge, strategy, and the theory of the firm. Strategic Management J. 17(Winter special issue) 93-107.
54. Macher, J. T., C. S. Boerner. 2006. Experience and scale and scope economies: Trade-offs and performance in development. Strategic Management J. 27(9) 845-865.
55. Mansfield, E., M. Schwartz, S. Wagner. 1981. Imitation costs and patents: An empirical study. Econom. J. 91(364) 907-918.
56. Mayor, S. 2006. NICE removes , blockers as first line treatment for hypertension. British Medical J. 333(7557) 8.
57. Merton, R. K. 1973. The Sociology of Science: Theoretical and Empirical Investigations. Chicago University Press, Chicago.
58. Meyer, J. W., B. Rowan. 1977. Institutionalized organizations: Formal structure as myth and ceremony. Amer. J. Sociol. 83(2) 340-363.
59. Mitchell, W. 1989. Whether and when? Probability and timing of incumbents' entry into emerging industrial subfields. Admin. Sci. Quart. 34(2) 208-230.
60. Nagourney, E. 2005. Front line against hypertension is under siege. New York Times (November 1) F6.
61. Nelson, R. R. 1959. The simple economics of basic scientific research. J. Political Econom. 67(3) 297-306.
62. Nelson, R. R. 1982. Government and Technical Progress: A Cross-Industry Analysis. Pergamon, New York.
63. Nelson, R. R. 1991. Why do firms differ, and how does it matter? Strategic Management J. 12(S2) 61-74.
64. Nelson, R. R., S. G. Winter. 1982. An Evolutionary Theory of Economic Change. Belknap Press of Harvard University Press, Cambridge, MA.
65. Noll, R. G. 1989. Economic perspectives on the politics of regulation. R. Schmalensee, R. Willig, eds. Handbook of Industrial Organization, Vol. 2. Elsevier, Amsterdam, 1253-1287.
66. Olson, M. K. 1999. Agency rulemaking, political influences, regulation, and industry compliance. J. Law Econom. 15(3) 573-601.
67. Olson, M. K. 2004. Are novel drugs more risky for patients than less novel drugs? J. Health Econom. 23(6) 1135-1158.
68. Penner-Hahn, P., J. M. Shaver. 2005. Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms. Strategic Management J. 26(2) 121-140.
69. Peteraf, M. A. 1993. The cornerstones of competitive advantage: A resource-based view. Strategic Management J. 14(3) 179-191.
70. Pisano, G. P. 2006. Science Business: The Promise, the Reality and the Future of Biotech. Harvard Business School Press, Boston.
71. Rao, H. 1994. The social construction of reputation: Certification contests, legitimation, and the survival of organizations in the American automobile industry: 1895-1912. Strategic Management J. 15(S1) 29-44.
72. Ray, W. A., W. Downey, M. R. Griffin, L. J. Melton. 1989. Longterm use of thiazide diuretics and risk of hip fracture. Lancet 333(8640) 687-690.
73. Reuben, B. G., H. A. Wittcoff. 1989. Pharmaceutical Chemicals in Perspective. John Wiley & Sons, New York.
74. Rosenberg, N.. 1982. How exogenous is science? N. Rosenberg, ed. Inside the Black Box: Technology and Economics. Cambridge University Press, Cambridge, UK, 141-162.
75. Rosenberg, N. 1990. Why do firms do basic research (with their own money)? Res. Policy 19(2) 165-174.
76. Scriabine, A. 1999. Discovery and development of major drugs currently in use. R. Landau, B. Achilladelis, A. Scriabine, eds. Pharmaceutical Innovation: Revolutionizing Human Health. Chemical Heritage Press, Philadelphia, 148-270.
77. Sharma, A., N. Lacey. 2004. Linking product development outcomes to market valuation of the firm: The case of U.S. pharmaceutical industry. J. Product Innovation Management 21(5) 297-308.
78. Skinner, D. J. 1994. Why firms voluntarily disclose bad news. J. Accounting Res. 32(1) 38-60.
79. Strang, D., J. W. Meyer. 1993. Institutional conditions for diffusion. Theory Soc. 22(4) 487-511.
80. Thomke, S., W. Kuemmerle. 2002. Asset accumulation, interdependence and technological change: Evidence from pharmaceutical drug discovery. Strategic Management J. 23(7) 619-635.
81. Thompson, J. D. 1967. Organizations in Action. McGraw-Hill, New York.
82. Trajtenberg, M. 1990. A penny for your quotes: Patent citations and the value of innovations. RAND J. Econom. 21(1) 172-187.
83. Travis, J. 2005. Saving the mind faces high hurdles. Science 309(5735) 731-734.
84. Tripsas, M. 1997. Unraveling the process of creative destruction: Complementary assets and firm survival in the typesetter industry. Strategic Management J. 18(S1) 119-142.
85. Tushman, M. L., P. Anderson. 1986. Technological discontinuities and organizational environments. Admin. Sci. Quart. 31(3) 439-465.
86. Vaczek, D. 2005. Top 200 prescription drugs of 2004. Pharmacy Times (May 1) http://www.pharmacytimes.com/publications/issue/2005/2005-05/2005-05-9582.
87. van den Belt, H., A. Rip. 1987. The Nelson-Winter-Dosi model and synthetic dye chemistry. W. E. Bijker, T. P. Hughes, T. J. Pinch, eds. The Social Construction of Technological Systems: New Directions in the So0ciology and History of Technology. MIT Press, Cambridge, MA, 135-158.
88. Vogel, G. 1997. Publishing sensitive data: Who calls the shots? Longsuppressed study finally sees light of day. Science 276(5312) 525-526.
89. Wooldridge, J. M. 2002. Econometric Analysis of Cross Section and Panel Data. MIT Press, Cambridge, MA.
90. Ziman, J. M. 1968. Public Knowledge: An Essay Concerning the Social Dimension of Science. Cambridge University Press, Cambridge, UK.